Research Article
Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases
Table 2
TPE indications and TPE replacement solutions.
| TPE indications | TPE replacement solution, n (%) | Total, n=66 | Albumin 5%, n=39 | Albumin 5% plus Fresh frozen plasma, n=8 | 4% succinylated gelatin, n=10 | Fresh frozen plasma, n=9 |
| DAH | 8 (20.51) | 7 (87.5) | 3 (30) | 2 (22.22) | 20 (30.3) | Neuropsychiatric SLE | 5 (12.81) | 1 (12.5) | 2 (20) | 1 (11.11) | 9 (13.6) | Rapidly progressive glomerulonephritis | 6 (15.38) | 0 (0) | 1 (10) | 0 (0) | 7 (10.6) | Thrombotic microangiopathy | 1 (2.56) | 0 (0) | 1 (10) | 3 (33.33) | 5 (7.6) | CAPS | 3 (7.69) | 0 (0) | 0 (0) | 2 (22.22) | 5 (7.6) | Lupus nephritis (WHO Class IV) | 2 (5.13) | 0 (0) | 1 (10) | 1 (11.11) | 4 (6.1) | Severe skin lupus | 2 (5.13) | 0 (0) | 1 (10) | 0 (0) | 3 (4.5) | Inflammatory myopathies | 3 (7.69) | 0 (0) | 0 (0) | 0 (0) | 3 (4.5) | Gastrointestinal lupus | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Severe scleroderma | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Severe SLE | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Autoimmune meningoencephalitis | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Neuromyelitis Optical | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Rejection of the kidney allograft | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Type B insulin resistance | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Evans syndrome | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | Legs vasculitis | 0 (0) | 0 (0) | 1 (10) | 0 (0) | 1 (1.5) | CNS Vasculitis | 1 (2.56) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) |
|
|
TPE: therapeutic plasma exchange; DAH: diffuse alveolar hemorrhage; SLE: systemic lupus erythematosus; CAPS: catastrophic antiphospholipid syndrome; WHO: World Health Organization; CNS: central nervous system.
|